InnoCare Pharma Limited
InnoCare Pharma Limited (HKSE: 9969) is trading at HK$14.79, about ₹181 at today's HKD/INR rate, as of 30 Sep 2026, 4:08 AM ET, up 2.21% today. Indian residents can buy InnoCare Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$14.19
Today's high
HK$14.95
52 week low
HK$9.65
52 week high
HK$20.18
9969 opened at HK$14.43, closed previously at HK$14.47, and has traded between HK$9.65 and HK$20.18 over the past 52 weeks.
About
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
Key statistics
Avg. volume
8.95M
Market cap
HK$22.09B
P/E Ratio
24.30
Price-to-sales ratio
6.84
Enterprise value
CN¥14.00B
Free cash flow yield
0.67%
Debt-to-equity ratio
0.29
Return on equity
8.10%
ROIC
4.43%
Beta
0.39
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥2.30B
Earnings per share
CN¥0.36
Free cash flow
CN¥130.80M
Net profit margin
32.93%
Gross margin
89.85%
EBITDA
CN¥555.89M
Revenue growth
127.60%
Similar securities
This is not an investment recommendation
How to buy InnoCare Pharma from India
Indian residents can buy InnoCare Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for InnoCare Pharma and place an order
Find InnoCare Pharma by name or by its ticker, 9969, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. InnoCare Pharma trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your InnoCare Pharma position in HKD and INR. InnoCare Pharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in InnoCare Pharma from India
Trading and taxes when buying InnoCare Pharma from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneInnoCare Pharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy InnoCare Pharma stock?
Yes. InnoCare Pharma (9969) has been listed on the Hong Kong Stock Exchange since 2020, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one InnoCare Pharma share cost in rupees?
One InnoCare Pharma share is HK$14.79 — about ₹181 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the InnoCare Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying InnoCare Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of InnoCare Pharma?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on InnoCare Pharma shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the InnoCare Pharma price. Paasa issues a capital-gains statement for your return.
Does InnoCare Pharma pay a dividend?
No. InnoCare Pharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade InnoCare Pharma from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is InnoCare Pharma a Hong Kong SAR China company, and does that change how it is taxed?
InnoCare Pharma trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. InnoCare Pharma trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare InnoCare Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your InnoCare Pharma holding, its cost and its closing value.
How do I sell InnoCare Pharma and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.